Value of Cerebrospinal Fluid α-Synuclein Species as Biomarker in Parkinson’S Diagnosis and Prognosis

References

• Parnetti L , CastriotoA, ChiasseriniDet al. Cerebrospinal fluid biomarkers in Parkinson disease. Nature Rev. Neurol.9(3), 131–140 (2013).
   PubMed Web of Science ®Google Scholar
• Alonso-Navarro H , Jimenez-JimenezFJ, Garcia-MartinE, AgundezJA. Genomic and pharmacogenomic biomarkers of Parkinson’s disease. Curr. Dru Metabol.15(2), 129–181 (2014).
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF . Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord. doi:10.1016/j.parkreldis.2015.09.004 (2015) ( Epub ahead pf print).
   Google Scholar
• Schrag A , SauerbierA, ChaudhuriKR. New clinical trials for nonmotor manifestations of Parkinson’s disease. Mov. Disord.30(11), 1490–1504 (2015).
   PubMed Web of Science ®Google Scholar
• Hely MA , ReidWG, AdenaMA, HallidayGM, MorrisJG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord.23(6), 837–844 (2008).
   PubMed Web of Science ®Google Scholar
• Aarsland D , AndersenK, LarsenJP, LolkA, Kragh-SorensenP. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60(3), 387–392 (2003).
   PubMedGoogle Scholar
• Parkinson’s Progression Markers Initiative . http://www.ppmi-info.org.
   Google Scholar
• The Parkinson’s Progression Marker Initiative (PPMI)–assessment of clinical, imaging and CSF PD biomarkers. http://www.ppmi-info.org/wp-content/uploads/2014/06/729_MDS-2014-Poster-PPMI-Overview.pdf.
   Google Scholar
• Vekrellis K , XilouriM, EmmanouilidouE, RideoutHJ, StefanisL. Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol.10(11), 1015–1025 (2011).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH , LavedanC, LeroyEet al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science276(5321), 2045–2047 (1997).
   PubMed Web of Science ®Google Scholar
• Spillantini MG , SchmidtML, LeeVM, TrojanowskiJQ, JakesR, GoedertM. Alpha-synuclein in Lewy bodies. Nature388(6645), 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• El-Agnaf OM , SalemSA, PaleologouKEet al. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J.17(13), 1945–1947 (2003).
   PubMedGoogle Scholar
• Borghi R , MarcheseR, NegroAet al. Full length α-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci. Lett.287(1), 65–67 (2000).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B . Quantification of alpha-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson’s disease?Parkinsonism Relat. Disord.20(Suppl. 1), S76–S79 (2014).
   PubMedGoogle Scholar
• Tokuda T , SalemSA, AllsopDet al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Commun.349(1), 162–166 (2006).
   PubMed Web of Science ®Google Scholar
• Parnetti L , ChiasseriniD, BellomoGet al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov. Disord.26(8), 1428–1435 (2011).
   PubMed Web of Science ®Google Scholar
• Aerts MB , EsselinkRA, AbdoWF, BloemBR, VerbeekMM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging33(2), 430e431–e433 (2012).
   Web of Science ®Google Scholar
• Compta Y , ValenteT, SauraJet al. Correlates of cerebrospinal fluid levels of oligomeric– and total-alpha-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J. Neurol.262(2), 294–306 (2015).
   PubMed Web of Science ®Google Scholar
• Magdalinou NK , PatersonRW, SchottJMet al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatr. doi:10.1136/jnnp-2014-309562 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Hall S , SurovaY, OhrfeltA, ZetterbergH, LindqvistD, HanssonO. CSF biomarkers and clinical progression of Parkinson disease. Neurology84(1), 57–63 (2015).
   PubMed Web of Science ®Google Scholar
• Kruse N , MollenhauerB. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human alpha-synuclein in cerebrospinal fluid. J. Immunol. Method. doi:10.1016/j.jim.2015.08.003 (2015) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Tokuda T , QureshiMM, ArdahMTet al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology75(20), 1766–1772 (2010).
   PubMed Web of Science ®Google Scholar
• Parnetti L , ChiasseriniD, PersichettiEet al. Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson’s disease. Mov. Disord.29(8), 1019–1027 (2014).
   PubMed Web of Science ®Google Scholar
• Vaikath NN , MajbourNK, PaleologouKEet al. Generation and characterization of novel conformation-specific monoclonal antibodies for alpha-synuclein pathology. Neurobiol. Dis.79, 81–99 (2015).
   PubMed Web of Science ®Google Scholar
• Fagerqvist T , LindstromV, NordstromEet al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation. J. Neurochem.126(1), 131–144 (2013).
   PubMed Web of Science ®Google Scholar
• Hong Z , ShiM, ChungKAet al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain133(Pt 3), 713–726 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Y , ShiM, ChungKAet al. Phosphorylated alpha-synuclein in Parkinson’s disease. Sci. Transl. Med.4(121), 121ra120 (2012).
   Web of Science ®Google Scholar
• Bidinosti M , ShimshekDR, MollenhauerBet al. Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J. Biol. Chem.287(40), 33691–33705 (2012).
   PubMed Web of Science ®Google Scholar
• van Dijk KD , BidinostiM, WeissA, RaijmakersP, BerendseHW, van de BergWD. Reduced alpha-synuclein levels in cerebrospinal fluid in Parkinson’s disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol.21(3), 388–394 (2014).
   PubMed Web of Science ®Google Scholar
• Aasly JO , JohansenKK, BronstadGet al. Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci.6, 248 (2014).
   PubMed Web of Science ®Google Scholar
• Buddhala C , CampbellMC, PerlmutterJS, KotzbauerPT. Correlation between decreased CSF alpha-synuclein and Abeta(1)(-)(4)(2) in Parkinson disease. Neurobiol. Aging36(1), 476–484 (2015).
   PubMed Web of Science ®Google Scholar
• Hall S , OhrfeltA, ConstantinescuRet al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol.69(11), 1445–1452 (2012).
   PubMedGoogle Scholar
• Hu Y , YuSY, ZuoLJet al. Parkinson disease with REM sleep behavior disorder: features, alpha-synuclein, and inflammation. Neurology84(9), 888–894 (2015).
   PubMed Web of Science ®Google Scholar
• Kang JH , IrwinDJ, Chen-PlotkinASet al. Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol.70(10), 1277–1287 (2013).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B , CullenV, KahnIet al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol.213(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B , LocascioJJ, Schulz-SchaefferW, Sixel-DöringF, TrenkwalderC, SchlossmacherMG. α-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol.10(3), 230–240 (2011).
   PubMed Web of Science ®Google Scholar
• Mollenhauer B , TrautmannE, TaylorPet al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett.532, 44–48 (2013).
   PubMed Web of Science ®Google Scholar
• Mondello S , ConstantinescuR, ZetterbergH, AndreassonU, HolmbergB, JerominA. CSF alpha-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders. Parkinsonism Relat. Disord.20(4), 382–387 (2014).
   PubMed Web of Science ®Google Scholar
• Ohrfelt A , GrognetP, AndreasenNet al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders–a marker of synapse loss? Neurosci. Lett. 450(3), 332–335 (2009).
   PubMed Web of Science ®Google Scholar
• Park MJ , CheonSM, BaeHR, KimSH, KimJW. Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson’s disease. J. Clin. Neurol.7(4), 215–222 (2011).
   PubMed Web of Science ®Google Scholar
• Parnetti L , FarottiL, EusebiPet al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s disease. Front. Aging Neurosci.6, 53 (2014).
   PubMed Web of Science ®Google Scholar
• Reesink FE , LemstraAW, van DijkKDet al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J. Alzheimers Dis.22(1), 87–95 (2010).
   PubMed Web of Science ®Google Scholar
• Shi M , BradnerJ, HancockAMet al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol.69(3), 570–580 (2011).
   PubMed Web of Science ®Google Scholar
• Stewart T , LiuC, GinghinaCet al. Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol.184(4), 966–975 (2014).
   PubMed Web of Science ®Google Scholar
• Stewart T , SossiV, AaslyJOet al. Phosphorylated alpha-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathol. Commun.3, 7 (2015).
   PubMed Web of Science ®Google Scholar
• Tateno F , SakakibaraR, KawaiT, KishiM, MuranoT. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord.26(3), 213–216 (2012).
   PubMed Web of Science ®Google Scholar
• Toledo JB , KorffA, ShawLM, TrojanowskiJQ, ZhangJ. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer’s disease. Acta Neuropathol.126(5), 683–697 (2013).
   PubMed Web of Science ®Google Scholar
• Wang H , WangK, XuWet al. Cerebrospinal fluid alpha-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. J. Neurochem.122(1), 19–23 (2012).
   PubMed Web of Science ®Google Scholar
• Wennstrom M , SurovaY, HallSet al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE8(1), e53250 (2013).
   PubMed Web of Science ®Google Scholar
• Gao L , TangH, NieKet al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson’s disease diagnosis: a systematic review and meta-analysis. Int. J. Neurosci.125(9), 645–654 (2015).
   PubMed Web of Science ®Google Scholar
• Sako W , MurakamiN, IzumiY, KajiR. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov. Disord.29(13), 1599–1605 (2014).
   PubMed Web of Science ®Google Scholar
• del Campo M , MollenhauerB, BertolottoAet al. Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update. Biomarkers Med.6(4), 419–430 (2012).
   PubMed Web of Science ®Google Scholar
• Laurens B , ConstantinescuR, FreemanRet al. Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol. Dis.80, 29–41 (2015).
   PubMed Web of Science ®Google Scholar
• Lleo A , CavedoE, ParnettiLet al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Rev. Neurol.11(1), 41–55 (2015).
   PubMed Web of Science ®Google Scholar